Atopic dermatitis differential diagnosis: five eczema mimics to know

Advances in atopic dermatitis (AD) treatment have transformed what's possible in clinic. Biologics and small-molecule JAK inhibitors now bring control within reach for patients who would once have been labelled treatment-resistant. Yet a meaningful number of cases remain genuinely difficult to manage, and the reason is not always the treatment itself. Sometimes another condition is mimicking eczema. Sometimes it's sitting alongside it, complicating the picture. And sometimes the diagnosis is right, but choosing the correct advanced therapy for that particular patient is the harder decision.

Why atopic dermatitis can still be so hard to manage

There is no single blood test or biopsy that confirms biomarkers for atopic dermatitis and predict treatment success. Diagnosis relies on the clinical picture: distribution, morphology, history and response to treatment. That clinical judgement is exactly where things get complicated. Several conditions can look strikingly similar to AD, and it is not uncommon for a patient to have more than one skin condition at once. That's only half the challenge, though. Once the diagnosis is confirmed, the expanding range of biologics and small molecules for AD means more decisions, not fewer: which patients are suitable, what to monitor, and how to navigate the clinical scenarios that don't fit neatly into a guideline flowchart.

Five conditions that can mimic, or coexist with, atopic dermatitis

In atopic dermatitis differential diagnosis, some conditions mimic AD outright. Others turn up alongside it. Both possibilities are worth ruling in or out before moving to systemic treatment, sinc e a therapy aimed squarely at AD will not touch a coexisting condition it was never designed to treat.

1. Allergic and irritant contact dermatitis

Often confused with AD because it also produces itch, erythema and oedema. Look for a distribution that follows contact with an allergen or irritant, a more sudden onset, and a poor response to emollients alone. Patch testing can distinguish allergic contact dermatitis from AD when the history and pattern are unclear.

2. Seborrhoeic dermatitis

Favours sebum-rich sites — the scalp, eyebrows, nasolabial folds and central chest — with greasy, yellowish scale rather than the dry, lichenified plaques typical of flexural AD. It is Malassezia-associated and often responds to antifungal and mild anti-inflammatory treatment rather than standard emollient-first eczema care.

3. Psoriasis

Well-demarcated, salmon-pink plaques with silvery scale, classically on extensor surfaces, the scalp and lower back, with possible nail pitting or onycholysis. It can coexist with AD, and itch does not reliably separate the two, so distribution and scale character carry more diagnostic weight.

4. Scabies

An intensely itchy eruption, often worse at night, with burrows visible in the finger webs, wrists and genital area. Ask about similar symptoms in household or close contacts. In infants, older adults and immunosuppressed patients, scabies can mimic eczema closely, and missed cases continue to spread.

5. Cutaneous T-cell lymphoma (mycosis fungoides)

The mimic clinicians are most likely to miss. It presents as persistent, sometimes asymmetric, patches or thin plaques, often on non-sun-exposed skin, that do not improve with standard topical treatment. Adult-onset “eczema” that will not settle deserves a biopsy before it is written off as difficult AD.

And these are just five examples. There are even more conditions to consider!

Diagnosis is only step one: choosing the right advanced therapy

For patients with moderate to severe AD who don't respond to topical treatment, the UK now has a genuine choice of systemic options: biologics such as lebrikizumab, tralokinumab, nemolizumab and dupilumab, and small-molecule JAK inhibitors such as upadacitinib, abrocitinib and baricitinib. That choice is welcome, but it shifts the clinical question: “which one, for this patient,” weighing comorbidities, prior treatment history, monitoring requirements and what matters to the patient. Getting the diagnosis right is what makes that second question answerable in the first place.

atopic dermatitis differential diagnosis: Red flags that should prompt a second look

•    No improvement despite confirmed adherence to an adequate emollient and topical steroid regimen

•    Asymmetric or unusual distribution for eczema, for example confined to one limb or sparing the flexures

•    New onset in adulthood with no personal or family history of atopy

•    Signs that do not fit eczema: well-demarcated plaques, burrows, greasy scale, or a single persistent patch

•    Systemic symptoms such as unexplained weight loss or lymphadenopathy

Frequently asked questions

Q: What is the difference between eczema and atopic dermatitis?

A: None. “Eczema” is the general term for a group of inflammatory skin conditions, and atopic dermatitis is the most common type, usually linked to a personal or family history of asthma, hay fever or atopy. In everyday UK practice, the two terms are used interchangeably.

Q: What conditions are most commonly mistaken for atopic dermatitis?

A: Allergic and irritant contact dermatitis, seborrhoeic dermatitis, psoriasis, scabies and cutaneous T-cell lymphoma are five of the most frequently confused. Fungal infection is also worth considering, particularly in localised or asymmetric presentations.

Q: How can I tell scabies apart from eczema in clinic?

A: Check the finger webs, wrists and genital area for burrows, and ask whether anyone else in the household is itching. Symptoms that worsen rather than improve on standard eczema treatment are also a clue.

Q: Can psoriasis and atopic dermatitis occur in the same patient?

A: Yes. The two conditions can and do coexist, which is one reason treatment-resistant “eczema” sometimes needs a fresh clinical look.

Q: When should treatment-resistant eczema be biopsied?

A: Consider biopsy when the rash is persistent, asymmetric and unresponsive to an adequate trial of standard therapy, particularly in adults with new-onset disease and no personal or family history of atopy.

Q: Is atopic dermatitis curable?

A: There is no cure, but AD is manageable. Most patients achieve good control with a structured routine of emollients and topical anti-inflammatories, with phototherapy or systemic treatment reserved for more severe or resistant disease.

Q: What are the newer treatment options for atopic dermatitis?

A: For patients with moderate to severe disease who don't respond to topical treatment, options now include biologics such as lebrikizumab, tralocinumab, nemolizumab and dupilumab, and small-molecule JAK inhibitors such as upadacitinib, abrocitinib and baricitinib. Each has a different mechanism, monitoring requirement and place in the treatment pathway.

Q: Why might a patient not respond to advanced AD therapy?

A: Non-response is sometimes a treatment issue, but it is also worth revisiting the diagnosis. A coexisting or misdiagnosed mimic, such as psoriasis, scabies or cutaneous T-cell lymphoma, will not improve on a therapy targeted at atopic dermatitis.

Get the full picture at The Eczema Enigma

On 24 September 2026, Bright Med brings together Dr Tom King and Dr Sura Sahib, both Consultant Dermatologists at Sheffield Teaching Hospitals, for The Eczema Enigma: Diagnosis, mimics and the treatment decisions you won’t find in the guidelines.

This CPD-accredited, one-day workshop in London, is built around both halves of this challenge. You'll cover AD pathophysiology, complications and comorbidities; how to recognise the conditions that mimic or coexist with AD; and how to prescribe and monitor advanced therapeutics, including biologics and small molecules, across the complex clinical scenarios that guidelines don't fully cover. The day closes with an interactive, case-based multidisciplinary treatment workshop with the full faculty, plus a first look at the Bright Med AD Decision Aid Tool.

The workshop is suitable for dermatologists, GPs, nurses, pharmacists and all healthcare professionals with an interest in dermatology. Tickets are £35 for consultants and GPs and £25 for nurses, pharmacists and trainees

Register Now